TRANSFERRIN RECEPTOR, in Visit Clinic

The transferrin receptor (TfR, CD71) binds iron‑loaded transferrin on the cell surface and mediates receptor‑mediated endocytosis, allowing iron release in endosomes and transport into the cytoplasm. It’s essential for hemoglobin synthesis, mitochondrial function and cell proliferation. Expression is regulated by cellular iron needs and is high in rapidly dividing cells; the receptor then recycles to the membrane.

A high soluble transferrin receptor indicates increased cellular iron demand. It commonly reflects iron deficiency or iron‑deficiency anemia and rises with increased erythropoiesis (for example after bleeding or in hemolytic disorders). Because it’s less affected by inflammation than ferritin, an elevated level helps distinguish iron‑deficiency anemia from anemia of chronic disease. Further evaluation and treatment should be guided by a clinician.

No. Transferrin is an iron-transport protein, not a specific tumor marker. Levels may change with chronic illness, inflammation, malnutrition or cancer, and transferrin-related measures (e.g., transferrin receptor) are researched, but transferrin itself isn’t used clinically to diagnose or monitor cancer. Established tumor markers (PSA, CEA, CA‑125, etc.) are used for cancer assessment instead.

Transferrin receptor 1 (TfR1) is widely expressed, high‑affinity, mediates cellular iron uptake via clathrin‑dependent endocytosis and is regulated post‑transcriptionally by iron‑responsive proteins, essential for erythropoiesis. Transferrin receptor 2 (TfR2) is mainly hepatic (and some erythroid), lower affinity, functions as an iron sensor that helps regulate hepcidin and systemic iron balance; TFR2 mutations cause iron overload.

In iron deficiency, the liver increases transferrin production to raise total iron‑binding capacity and maximize transport of scarce iron to the bone marrow. Low serum iron and reduced transferrin saturation trigger hepatic upregulation of transferrin synthesis, while tissues increase transferrin receptor expression to enhance iron uptake. Clinically this yields high transferrin/TIBC with low serum iron and low transferrin saturation.

TIBC (total iron‑binding capacity) measures blood’s capacity to bind iron, reflecting circulating transferrin levels; it rises in iron deficiency and falls in iron overload or inflammation. Transferrin receptors (often measured as soluble transferrin receptor, sTfR) indicate cellular iron demand and erythropoietic activity; sTfR rises in iron deficiency but is less affected by inflammation, helping distinguish anemia causes.